Trial Profile
A first-in-human study of ANN-002 in treatment of hereditary angioedema
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 26 Nov 2018
Price :
$35
*
At a glance
- Drugs ADVM 053 (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions; First in man
- 08 Nov 2018 According to an Adverum Biotechnologies media release, the company will not submit an IND application, as it plans to conduct additional preclinical studies to determine the best gene therapy candidate to advance for the rare disease programs.
- 01 Nov 2018 According to an Adverum Biotechnologies media release, the company will not submit an IND application for ADVM-053 for the treatment of hereditary angioedema (HAE) in the fourth quarter of 2018.
- 08 Nov 2017 According to an Adverum Biotechnologies media release, the Company also plans to file an IND application with the FDA in the second half of 2018.